文献速递临床试验与 GCP

藤府降压片联合缬沙坦/氨氯地平治疗2级高血压的疗效与安全性:随机对照试验研究方案

Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-02-22

这项随机双盲、安慰剂对照、多中心试验将在7个临床中心纳入288例2级高血压(肝阳上亢证)患者,按1:1随机接受藤府降压片或安慰剂(每日三次,共28天),两组均联用缬沙坦/氨氯地平80/5 mg。主要疗效终点为第4周坐位平均收缩压和舒张压较基线的下降值,旨在评估联合治疗的疗效与安全性。

要点

  • 纳入288例2级高血压(肝阳上亢证)患者,7个中心参与。
  • 藤府降压片或安慰剂每日三次、共28天,两组均联用缬沙坦/氨氯地平80/5 mg。
  • 主要终点为第4周坐位平均收缩压和舒张压较基线的下降值。

核心结论

  • 这是首个评估中药提取物联合缬沙坦/氨氯地平治疗2级高血压的安慰剂对照随机试验,作者认为研究可能有助于为2级高血压的补充预防措施提供循证建议。

研究设计与样本

  • 随机双盲、安慰剂对照、多中心试验,共纳入288例2级高血压患者,在7个临床试验中心开展。
  • 采用分层随机方法,以分中心为分层因素,合格患者按1:1随机分配。
  • 干预为藤府降压片或安慰剂每日三次、共28天,两组均联用缬沙坦/氨氯地平80/5 mg。

主要发现

  • 主要疗效终点为第4周坐位平均收缩压和坐位平均舒张压较基线的下降值。
  • 整个试验期间监测不良事件和实验室检查结果。

关键数值与推荐

  • 国际指南(包括2018年中国高血压管理指南)推荐对2级高血压且血压≥160/100 mmHg的患者优化药物选择和联合治疗,包括缬沙坦/氨氯地平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence rate of hypertension in the Chinese population is on the rise, and the control rate of hypertension is low. International guidelines, including the 2018 Chinese Guidelines for the Management of Hypertension, recommend optimized drug selection and combination therapy for patients with stage 2 hypertension and blood pressure ≥ 160/100 mmHg, including valsartan/amlodipine (Val/Aml). The traditional Chinese medicine (TCM) compound Tengfu Jiangya tablet (TJT; No. Z20110021, Shandong Provincial Food and Drug Administration) is prepared in the medical institution of Affiliated Hospital of Shandong University of Traditional Chinese Medicine. It is an effective compound preparation of TCM for the treatment of hypertension in the national clinical research base of TCM. The aim of this study was to evaluate the efficacy and safety of TJT combined with Val/Aml in the treatment of stage 2 hypertension with hyperactivity of liver yang. METHODS: This randomized double-blind, placebo-controlled, multicenter trial will be conducted with a total of 288 participants with stage 2 hypertension at seven clinical trial centers. The stratified random method will be used, and the subcenter will be taken as the stratification factor. Eligible patients will be randomly assigned (1:1) into groups receiving either TJT or placebo three times daily for 28 days, both combined with Val/Aml 80/5 mg. The primary efficacy endpoint is the reduction in the mean sitting systolic blood pressure (msSBP) and the mean sitting diastolic blood pressure (msDBP) from baseline to week 4. Adverse events and laboratory test results will be monitored throughout the trial. DISCUSSION: This is the first placebo-controlled randomized trial conducted to evaluate the efficacy and safety of a Chinese herbal extract combined with Val/Aml in patients with stage 2 hypertension. Our study may help to provide evidence-based recommendations of a complementary preventive measure for stage 2 hypertension. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000030611 . Registered on 8 March 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang Y, Hua Z, Chen W, et al. Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35193665. doi:10.1186/s13063-022-06089-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。